Background-Risk stratification is an integral component of clinical decision making in heart failure (HF). Women with HF have unique characteristics compared with men, and it is unknown whether common prognostic factors are equally useful in both populations. We aimed to investigate whether sex-specific risk models are more accurate for risk prediction in patients with advanced HF. Methods and Results-Patients with advanced HF referred to University of California, Los Angeles (UCLA; n=2255), were stratified by sex into derivation (referred in [2000][2001][2002][2003][2004][2005][2006][2007] and validation (referred in 2008-2011) cohorts. Cox regression analysis was used to ascertain key variables predictive of the primary end point of death/urgent transplantation/ ventricular assist device in the derivation cohorts and confirmed in the validation cohorts in men, women, and the total population. Women were younger, with higher ejection fraction and better event-free survival. Despite differences in baseline characteristics, the 4 strongest predictors of outcome in both women and men, as well as in the total cohort, were B-type natriuretic peptide, peak oxygen consumption by cardiopulmonary exercise testing (pkVO 2 ), New York Heart Association (NYHA) classification, and use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. In addition, the UCLA model performed better than the Seattle Heart Failure Model (SHFM) and the Heart Failure Survival Score (HFSS) in our cohort (c-indices of 0. 
H eart failure (HF) is the common and final pathway of a multitude of cardiovascular diseases affecting >6 million men and women in the United States. 1 HF mortality rates may be highly variable from patient to patient depending on the severity of HF; thus, risk models to assess prognosis during both short-term and long-term are integral to help guide medical decision making on aggressive management strategies such as ventricular assist device (VAD) implantation, heart transplantation, or end-of-life planning and hospice care, when appropriate.
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Clinical Perspective on p 95
Several risk models for HF mortality have been recently developed and show variable levels of success as evidenced by c-statistics ranging from 0.63 to 0.78. [4] [5] [6] [7] [8] The Seattle Heart Failure Model (SHFM) 9 and the Heart Failure Survival Score (HFSS) 10 are 2 generally accepted models used to predict risk in patients with advanced HF. Although these models have been previously validated in several HF cohorts, recent studies suggest that these risk models may not apply to the modern era of patients with advanced HF referred to HF treatment centers for heart transplant and VAD evaluation. 11, 12 In addition, many of these models were developed and validated in selective cohorts of patients from clinical trials and may not have equal use in nontrial real-world patients.
Because women are not as well represented in most clinical trials compared with men, 13 risk models derived without validation in sex-specific cohorts may not have the same predictive accuracy as sex-specific HF risk models in providing effective risk stratification. Men and women with advanced HF present with different baseline characteristics. Women tend to have better systolic function, higher rates of hypertension, and lower rates of ischemic pathogenesis of cardiomyopathy. [14] [15] [16] The purpose of this study was to develop sex-specific risk prediction tools in patients with advanced HF, with the hypothesis that sex-specific risk models would be more accurate in predicting outcomes in advanced HF.
Methods
Patient Cohort
The cohort for analysis included 2255 patients (1569 men and 686 women) referred to the Ahmanson-University of California, Los Angeles (UCLA) Cardiomyopathy Center for HF management and transplant evaluation between January 2000 and June 2011. A total of one hundred twenty-five variables (including demographics, medications, echocardiography, and laboratory values) were recorded within 3 months of initial consultation. Medical record review was approved by the Medical Institutional Review Board of the UCLA.
Medical history was extracted from medical record review, and follow-up was assessed through review of medical records and public access social security death index. Patients lost to follow-up were analyzed at the time they were last known to be alive and well. The 2 coprimary end points analyzed were (1) all-cause mortality and (2) the combined end point of death, urgent transplant, and VAD. Nonurgent transplants (status 1B and II) were censored and considered as a nonfatal end of follow-up for the combined end point.
Statistical Methods
For the purpose of this study and its analysis, patients were stratified by sex to assess baseline characteristics and for risk modeling. Summary baseline data are presented as mean with SD for continuous variables and as percentages of the total for categorical variables, with 2-sample t tests and χ 2 tests used for comparing baseline characteristics between men and women, as appropriate.
Analysis for this study was restricted to 39 variables (Table I in the Data Supplement) with the goal of minimizing the percentage of patients with missing data and to mainly include noninvasive parameters for ease of application to other HF populations. The variables included demographics, known prognostic factors in HF, variables predictive of outcomes on univariate analysis, as well as factors that differed according to sex in this cohort. B-type natriuretic peptide (BNP) was run at UCLA Medical Center (UCLA Clinical Laboratory and Pathology Services) on industry standard platforms. The reference range for BNP is negative <100 pg/mL and positive ≥100 pg/mL.
Although most patients had a relatively complete data set for the candidate variables, there were several with a small number of missing values. To include patients with missing values in the model selection and regression analysis, the method of multiple imputation was used (SAS version 9.3; SAS Institute, Cary, NC). Categorical variables were imputed to the nearest category, whereas continuous variables were restricted to the minimum and maximum of the observed data. To analyze peak oxygen consumption (pkVO 2 ), we stratified our cohort of patients into 5 analysis groups (16-20, 10-16, 6-10 , and <6 mL/kg per minute and patients missing pkVO 2 measurements), which we compared with patients with pkVO 2 >20 mL/kg per minute.
Univariate Cox regression analysis was used to calculate the relative hazard ratios to test for the interaction between risk prediction and sex. To generate sex-specific multivariate models, we further stratified our patient cohort into respective male and female derivation (referred to UCLA in 2000-2007) and male and female validation (referred to UCLA from 2008 to 2011) cohorts. From the initial 39 variables, backward stepwise Cox regression analysis based on the average Akaike information criterion among 10 imputed data sets was used to select the variables most predictive of the outcome of all-cause mortality in the male and female derivation cohorts; the Akaike information criterion is a measure of the relative quality of the statistical model. Backward stepwise Cox regression removes 1 variable at each step, with the goal of optimizing (ie, minimizing) the Akaike information criterion at each removal step until the most predictive variables remain in the model equation. Forward stepwise Cox regression analysis was used to confirm the variables selected for inclusion in the model. The models were then tested in their respective validation cohorts. The final model included 4 variables: angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use, New York Heart Association (NYHA) class, BNP, and pkVO 2 group. Risk scores were derived for each individual patient using the sex-specific equations derived from β-coefficients. 
. For the categorical variables ACEI/ARB, NYHA class, and pkVO 2 , patient is assigned the value 1 for the category he/she belongs and 0 for the other categories. The equation is designed so that NYHA class I patients are assigned 0 for all NYHA categories, and patients with pkVO 2 >20 are assigned 0 for all pkVO 2 categories. In variables with >2 categories (NYHA and pkVO 2 ), a P value for multiple categories was obtained. Subjects were then stratified into sex-specific quartiles based on their risk scores. Survival by risk score quartiles was then assessed by the Kaplan-Meier method, with P values given by the log-rank test. The predictive abilities of the models were assessed by concordance index (c-index). 17 Because the same 4 variables were found to have equal ability to predict risk of mortality in men versus women, we proceeded to create a risk model derived from the total (men and women) cohort. A final (total cohort) model was derived from a male and female derivation (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) and validation (2008) (2009) (2010) (2011) cohorts (see Table II Scores were then categorized into 4 quartiles, with quartile 1 representing a score from 0.69 to 3.14; quartile 2, 3.15 to 3.92; quartile 3, 3.93 to 4.74; and quartile 4, 4.75 to 6.56, and analyzed model discrimination by the Kaplan-Meier method.
In addition to generating risk scores based on each variable's β-coefficients, survival at any time t based on the assigned risk scores was estimated using the following equation:
Using this equation, we determined 5-year survival probabilities for each individual patient and stratified them into 5 groups based on probability of survival: >75%, 50% to 75%, 25% to 50%, 10% to 25%, and <10% and assessed the capability of our model to predict outcomes at 5 years by the Kaplan-Meier method. P values were given by the log-rank test.
The performance of our model was also validated by comparing the discrimination abilities of our model with that of the SHFM 9 and the HFSS. 10 In coding the SHFM for this comparative analysis, the following variables not collected in our patient cohort were imputed using the default values provided in the original publication for allopurinol use, lymphocyte percent, and uric acid. 9 Model discrimination capability was assessed by c-index. C-indices were reinforced by a 500 bootstrap resampling of each respective cohort (combined/ male/female derivation and combined/male/female validation) and reported as mean c-index, SD, with 95% confidence. R software (The R Project for Statistical Computing http://www.r-project.org) was used for all statistical analyses with the exception of imputation, performed with SAS 9.3 (SAS Institute, Cary, NC).
Results
Analysis of Characteristics
Baseline characteristics of men and women with HF are shown in Table 1 . Briefly, the cohort of men was older (54.1 versus 50.9 years; P<0.001), and men had significantly lower left ventricular ejection fraction (EF; 26.5% versus 30.9%; P<0.001) but higher peak pkVO 2 (13.0 versus 11.9 mL/kg per minute; P<0.001) compared with women. In addition, women had significantly lower levels of BNP, blood urea nitrogen, creatinine, hemoglobin, and albumin; ischemic pathogenesis was less common, but depression was more common in women.
The survival rate in the overall cohort (2000-2011) was 83.5%, 69.9%, and 58.4% at years 1, 3, and 5, respectively, and survival free from all-cause mortality, urgent transplantation, and VAD was 71.4%, 56.0%, and 45.5% at years 1, 3, and 5, respectively. Women had better survival compared with men (86.7% versus 82.2% at 1 year) and higher event-free survival compared with men (survival free from all-cause mortality, urgent transplantation, and VAD implantation, 75.8% versus 69.9% at 1 year). In the derivation cohort (n=1569; 2000-2007), 1-and 3-year overall survival was 84.2% and 70.5% and event-free survival was 72.3% and 57.4%. In the validation cohort (n=686; 2008-2011), 1-and 3-year survival was 81.8% and 62.7% and event-free survival was 68.9% and 43.8%.
Univariate Predictors of Mortality
Univariate Cox regression analysis to assess how each variable predicted the primary outcome of all-cause mortality was performed in the male and female cohorts separately (Table III in the Data Supplement) . Briefly, we found that increased age, NYHA class, heart rate, and lnBNP were all associated with higher risk of mortality, whereas higher sodium, cholesterol, and systolic blood pressure were all associated with lower risk of mortality (all P≤0.05). Use of ACEI/ARB and β-blockers was associated with improved survival, whereas diuretics, including metalozone, were associated with worse outcomes (all P≤0.001). However, with the exception of sodium and albumin, there was no significant interaction between men and women for any of the variables (Table III in 
Do Risk Models for Advanced HF Need to Be Sex-Specific?
The sex-specific multivariable Cox regression analyses for all-cause mortality inclusive of all variables are presented in Table IV in the Data Supplement. Several variables were significantly associated with outcome in both sexes, including age, ischemic pathogenesis, systolic blood pressure, and BNP levels. Of interest, having a biventricular pacemaker was significantly predictive of improved outcomes in the cohort of women but not men. Diabetes mellitus status and blood urea nitrogen predicted mortality in men but not in women.
We then performed backward stepwise Cox regression analysis to select for the most predictive variables for mortality in each sex from the complete list of variables. Despite the observed differences in clinical characteristics between men and women, the top 4 predictors in both cohorts were the same: ACEI/ARB use, NYHA class, pkVO 2 , and levels of BNP.
The male-specific 4-variable model yielded a c-index of 0.792 in the male derivation cohort. The female-specific model yielded a c-index of 0.802 in its respective derivation cohort. The final 4-variable models for men and women separately are demonstrated in Table V in the Data Supplement. The c-indices were virtually unchanged with the inclusion of additional variables (Table VI in the Data Supplement). Sex-specific risk score survival analyses by quartiles of risk score are presented in Figure  I in the Data Supplement. Furthermore, despite the slight differences between the male-and female-derived 4-variable models (Table V in the Data Supplement), the sex-specific 4-variable model for men showed equally strong risk discrimination in the opposite sex (women) validation cohort (c-index=0.832). The sex-specific model for women also showed similarly strong risk discrimination in the validation cohort of men (c-index=0.803; Table VII in the Data Supplement).
Derivation and Validation of Sex-Neutral Risk Prediction Model
Because our data suggested that the same 4 variables have equal predictive ability in men and women, our next step was to create a single unified model to predict the combined end point of all-cause mortality, VAD implantation, and urgent transplantation using a combined (men plus women) derivation (2000-2007) and validation (2008) (2009) (2010) (2011) cohorts. Baseline variables of the combined derivation and validation cohorts are shown in Table II in the Data Supplement. On multivariable Cox regression analysis using the same set of 39 variables as defined in Table I in the Data Supplement, the top 4 variables were identical to variables previously identified in the male and female cohorts: ACEI/ARB use, NYHA class, pkVO 2 , and levels of BNP (Table 2 ). Higher BNP level was determined to be the strongest predictor of event and was the last variable dropped in the backward selection. ACEI/ARB use was associated with 49% decreased risk. Compared with patients classified with NYHA class I, patients with NYHA class III (hazard 2 (presumed to be missing because of inability to exercise) was also highly associated with increased risk of the combined end point. Although not all levels of the categorical variables NYHA class and pkVO2 were significant predictors, the overall P values for both these variables were highly significant (P<0.0001). The degree of correlation among the 4 variables in the model and their correlation with the other variables studied are presented in Table VIII in the Data Supplement. We converted our 4-variable model into a point-based risk score. Stratification by quartile of score showed strong discrimination (P<0.0001) in the derivation cohort, validation cohort, and male and female cohorts (Figure 1) . Patients with higher-risk scores had increased probability of event. The c-index of our prediction model in the total derivation cohort for the composite end point was 0.787, whereas the c-indices of the model in the validation, female, and male cohorts, respectively, were 0.786, 0.796, and 0.791. Furthermore, the equal predictive capability in both male and female cohorts is preserved in the total cohort-derived model. C-indices for the outcome of all-cause mortality were all >0.79. The reliability of our c-indices was confirmed by 500 sample bootstrap resampling, and discrimination remained high with a c-index of 0.788 (95% confidence interval, 0.773-0.884) in the derivation cohort and a c-index of 0.810 (95% confidence interval, 0.776-0.840) in the validation cohort (Tables IX and X in the Data Supplement for sex-specific and total cohort models, respectively). Furthermore, we tested our model in subsets of patients not on ACEI/ARB to test the strength of β-blockers and diuretics. The results of this analysis are presented in Table XI in the Data Supplement).
As described in Methods, patients were assigned 5-year survival probabilities based on their risk scores and stratified into 5 groups; stratification by probability of survival also revealed excellent risk discrimination in terms of predicting actual survival (Figure 2) .
Model Comparisons
Our model and scoring system performance was assessed by comparing its ability to discriminate risk with the SHFM and the HFSS Score. Variables for SHFM and HFSS are provided in Table XII in the Data Supplement. The discrimination of the UCLA model was highest as measured by the c-index (Table 3) .
Discussion
Using risk models in HF allows for prediction of prognosis and progression of the disease. Risk models can aid medical decision making, including decisions on the need for and timing of more aggressive therapies such as heart transplantation, mechanical circulatory support, or need for end-of-life planning. We initially hypothesized that sex-specific risk models would provide more accurate risk discrimination in advanced HF; our hypothesis was based on the unique properties of men versus women with HF. However, we found that the same 4 variables predicted risk in men and women, and thus, we subsequently derived and validated this unified risk model that uses 4 variables to give an accurate estimation prognosis in this cohort of patients with advanced HF. Previous risk models have been derived and validated in clinical trial patient cohorts, including the widely used SHFM, 9 and may not be valid when extrapolated to real-world patients. Although the SHFM and other risk models incorporate sex as a variable, they have not been specifically evaluated in individual cohorts of men and women. Thus, assessing the use of sex-specific models or variables incorporated into a sex-neutral model to predict risk is a crucial aspect of improving the clinical management and outcomes of HF. In assessing our patient cohort, we found that women had significantly higher body mass index, left ventricular EF, and rates of depression while having significantly lower peak oxygen consumption (pkVO2) on cardiopulmonary exercise testing, BNP levels, rates of cardiac resynchronization therapy, and implantable cardioverter defibrillators. Surprisingly, despite these differences in baseline characteristics reported both in other studies and our own, we found the key predictive variables for morbidity and mortality of HF in both men and women to be identical. Using 4 variables NYHA class, pkVO 2 , BNP, and ACEI/ARB therapy, we derived a simple risk prediction model. Because these variables are commonly assessed and recorded in patients with HF, this makes our model advantageous for clinicians. Furthermore, our model was derived in a wide range of patients with a variety of clinical causes, symptoms, and outcomes managed at a university HF treatment center rather than clinical trial patients, suggesting that, in the future, our model may be applied to other independent cohorts.
The 4-variable models in men and women were equally strong at risk discrimination with c-indices in their respective training and testing cohorts ≥0.8, a stronger c-statistic than many other HF models. 3 Our findings suggested that these 4 factors can be used with equal utility for risk prediction in both men and women with HF and thus led us to pursue and derive A-D, Patients were assigned 5-year survival probabilities based on their risk scores and stratified into 5 survival groups based on probability of survival: >75%, 50% to 75%, 25% to 50%, 10% to 25%, and <10%. a multivariable risk prediction model from our total patient cohort, which resulted in selection of the same 4 variables. It is of note that our 4-variable model had similarly high c-indices in derivation and validation cohorts, despite differences in baseline characteristics between these cohorts in different eras of HF care (Table II in the Data Supplement) . 18 We subsequently validated this model in men and women separately, a point that most other models have not addressed.
PkVO 2 was 1 of the 4 highly predictive variables of outcome. The optimal pkVO 2 cutoff that should trigger consideration of heart transplant in women is controversial because it has been shown that women tend to have lower pkVO 2 than men but higher rates of survival. 19 In our model, we found that the pkVO 2 categories we used had equal utility in men and women when it is used in combination with the other 3 variables. Patients with missing pkVO 2 values had highest risk of the combined outcome, which is potentially attributable to sicker and higher-risk patients not having the capacity to undergo cardiopulmonary exercise testing. Women missing pkVO 2 had a 2.8× higher risk for mortality, and men missing pkVO 2 had a 4-fold increased probability of death (Table V in the Data Supplement) .
Multiple studies have demonstrated the extraordinary prognostic capability of cardiac biomarkers such as BNP, N-terminal pro-BNP, and cardiac troponins. 20, 21 Furthermore, a recent subanalysis of the clinical trial population participating in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure (GISSI-HF) trial found N-terminal pro-BNP to be the strongest predictor of outcomes in their subgroup with biomarkers. 22 This analysis of the GISSI population found that the 3 most powerful predictors in the total cohort were older age, higher NYHA class, and lower estimated glomerular filtration rate. Our model included ACEI/ARB use, which is likely a strong surrogate for renal function in real-world populations; patients may not be treated with ACEI/ARB because of impaired renal function and low systolic blood pressure, another adverse prognosticator in HF. Although EF receives much clinical attention, EF was not 1 of the top 4 predictors of outcome in our cohort. Other HF risk models derived from recent HF cohorts after the advent of BNP also do not include EF. This suggests that factors such as BNP level, exercise tolerance, and renal function may be more important than EF in medical decision making in advanced HF. 7, 22 We acknowledge that our study has several limitations. Although our patient cohort had a broad range of patients as exhibited in the assessment of baseline characteristics, the model was derived from a retrospective analysis of patients seen at a single university transplant referral center. A key limitation is that our model may not be generalized to HF with preserved EF because our cohort comes from a cohort of patients with reduced EF HF. Although women make up half of the total HF population, women are more likely to have HF with preserved EF. In advanced HF cohorts that primarily consist of HF with reduced EF, women generally constitute only 25% to 30%, as was the case in this cohort. This could challenge the extrapolation of our risk model to other cohorts of patients. On the contrary, our model was derived in patients seen for initial consults between 2000 and 2007 and then validated in patients seen between 2008 and 2011 with strong discrimination of risk, suggesting that application to future and different cohorts is possible. Furthermore, we used multiple imputations to include the small percentage of patients who were missing data for the variables that were selected for analysis. In addition, a few of the variables required 100% imputation to analyze the predictive ability of the SHFM in our patient cohort because they were not recorded at our center. Finally, although our model performed well in our testing cohorts, we were not able to externally validate it in an independent cohort of patients with HF. Further validation is necessary to ensure that our model can withstand multiple tests in other patient groups.
In summary, we have successfully established a simple risk prediction model in patients with advanced HF. Although women do have different baseline characteristics compared with men, the 4 parameters, ACEI/ARB use, BNP, pkVO 2 , and NYHA class, identified in our study predict outcomes in both men and women.
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